| Literature DB >> 26638862 |
Fabio Puglisi1, Caterina Fontanella2, Vito Amoroso3, Giulia Valeria Bianchi4, Giancarlo Bisagni5, Cristina Falci6, Andrea Fontana7, Daniele Generali8, Lorenzo Gianni9, Antonio Grassadonia10, Luca Moscetti11, Ilaria Portarena12, Emanuela Rossi13, Paolo Marchetti14.
Abstract
The introduction of trastuzumab into routine clinical practice has had a dramatic effect on the outlook for patients with HER2-positive breast cancer. Nevertheless, answers to some long unresolved questions about the optimal use of trastuzumab (such as its role in small tumors or low-risk disease, cardiac safety in the elderly, and treatment duration) have emerged only relatively recently. Moreover, with the availability of new highly effective HER2-directed therapies, including pertuzumab and trastuzumab-emtansine (T-DM1), the treatment algorithm for HER2-positive breast cancer continues to evolve. This review provides a summary of the latest evidence providing insight into the management of early and advanced HER2-positive breast cancer and delineates future perspectives of study and treatment for these patients.Entities:
Keywords: Breast cancer; Dual targeting; HER2; Lapatinib; Neoadjuvant; Pertuzumab; Trastuzumab; Trastuzumab-emtansine
Mesh：
Substances：
Year: 2015 PMID： 26638862 DOI： 10.1016/j.critrevonc.2015.10.016
Source DB: PubMed Journal: Crit Rev Oncol Hematol ISSN： 1040-8428 Impact factor: 6.312